MacroGenics Inc MGNX.OQ MGNX.O is expected to show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
The Rockville Maryland-based company is expected to report a 28.0% decrease in revenue to $7.7 million from $10.7 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for MacroGenics Inc is for a loss of 61 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MacroGenics Inc is $3.00, about 48% above its last closing price of $1.56
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.75 | -0.78 | -0.65 | Beat | 16.9 |
Dec. 31 2025 | -0.44 | -0.25 | Beat | 42.7 | |
Sep. 30 2024 | 0.11 | 0.21 | 0.90 | Beat | 324.5 |
Jun. 30 2024 | -0.54 | -0.59 | -0.89 | Missed | -51.2 |
Mar. 31 2024 | -0.64 | -0.64 | -0.84 | Missed | -30.7 |
Dec. 31 2023 | -0.26 | -0.15 | -0.75 | Missed | -388 |
Sep. 30 2023 | -0.06 | -0.10 | 0.28 | Beat | 392.9 |
Jun. 30 2023 | -0.47 | -0.52 | -0.69 | Missed | -32.4 |
This summary was machine generated August 1 at 11:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)